01 1Alliance revenue - Lynparza
02 14Lynparza
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 1,776
2019 Revenue in Millions : 1,198
Growth (%) : 48
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 2,348
2020 Revenue in Millions : 1,776
Growth (%) : 32
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 725
2019 Revenue in Millions : 444
Growth (%) : 63
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 989
2020 Revenue in Millions : 725
Growth (%) : 36
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 2,638
2021 Revenue in Millions : 2,348
Growth (%) : 12
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 1,116
2021 Revenue in Millions : 989
Growth (%) : 13
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 2,811
2022 Revenue in Millions : 2,638
Growth (%) : 7
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 1,199
2022 Revenue in Millions : 1,116
Growth (%) : 7
Main Therapeutic Indication : Oncology
Currency : USD
2015 Revenue in Millions : 0
2014 Revenue in Millions : 94
Growth (%) : New Launch
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 297
2016 Revenue in Millions : 218
Growth (%) : 36
LOOKING FOR A SUPPLIER?